表紙:3D細胞培養の世界市場(第3版):スキャフォールド(足場)型、製品、用途、目的、および主な地域別の業界動向と予測(2020年~2030年)
市場調査レポート
商品コード
973922

3D細胞培養の世界市場(第3版):スキャフォールド(足場)型、製品、用途、目的、および主な地域別の業界動向と予測(2020年~2030年)

3D Cell Culture Market by Scaffold Format, Products, Application Areas, Purpose, and Key Geographical Regions: Industry Trends and Global Forecasts (3rd Edition), 2020-2030

出版日: | 発行: Roots Analysis | ページ情報: 英文 516 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=115.27円
3D細胞培養の世界市場(第3版):スキャフォールド(足場)型、製品、用途、目的、および主な地域別の業界動向と予測(2020年~2030年)
出版日: 2020年10月01日
発行: Roots Analysis
ページ情報: 英文 516 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

バイオテクノロジーと材料科学の進歩により、さまざまな3次元(3D)細胞培養モデルの開発が可能になりました。これらのシステムは、自然組織の微小環境をより正確にシミュレートできることが実証されており、それにより、2Dシステムに関連する大部分の課題を克服するのに役立ちます。

さらに、3D細胞培養は、自然組織の微小環境をより適切にシミュレートできるため、創薬/毒性検査、再生医療の開発、組織工学、幹細胞調査などの実験調査で使用するためのより優れたinvivoモデルとして機能します。これにより、近い将来、このようなソリューションの採用が促進されると予測されています。

また、最近の研究では、感染性呼吸器疾患を研究するために、3D培養システムを使用してヒトの気管支組織と気道細胞をエミュレートしています。さらに、3D細胞培養とオルガノイドベースのスクリーニングシステムは、新しいコロナウイルスの病因の研究を容易にし、この面で進行中の医薬品開発の取り組みをサポートするために開発されています。COVID-19のパンデミックにより、このようなソリューションの需要が増加し、市場参入企業に有利な機会がもたらされる可能性が高いと考えられ、3D細胞培養市場全体は、今後数年間で大幅な成長が見込まれています。

当レポートは、世界の3D細胞培養市場について調査しており、技術開発、資金調達および投資、特許分析、事業セグメント・3D細胞培養フォーマット・製品タイプ・用途分野・目的・地域別の市場分析、競合情勢、主要企業のプロファイルなどの情報を提供しています。

目次

第1章 序文

  • 調査範囲
  • 調査手法
  • 回答された重要な質問
  • 章の概要

第2章 エグゼクティブサマリー

第3章 イントロダクション

  • 章の概要
  • 細胞培養タイプ
  • 培養中の細胞の形態
  • 2Dから3D細胞培養への移行
  • 三次元細胞培養の概要
  • 細胞培養の確立と維持
  • 細胞培養の健康を維持するための要件
  • 3D細胞培養システムの必要性
  • 3D細胞培養システムの利点と制限
  • 今後の展望

第4章 3D細胞培養システムの分類

  • 3D細胞培養分類
  • スキャフォールド(足場)型3D細胞培養
    • ヒドロゲル/ECMアナログ
    • 固体足場
    • マイクロパターン化された表面
    • マイクロキャリア
  • 非スキャフォールド(足場)型3D細胞培養
    • 耐付着性表面
    • 浮遊培養システム
    • マイクロ流体表面とOrgans-on-Chip
    • 3Dバイオリアクター
  • オルガノイド

第5章 3Dマトリックスとスキャフォールド(足場)の製造

  • 章の概要
  • 多孔質スキャフォールドの製造方法
  • 繊維状スキャフォールドの製造方法
  • ヒドロゲルの製造方法
  • カスタムスキャフォールドの製造方法
  • ミクロスフェアの製造方法
  • ネイティブスキャフォールドを製造方法

第6章 3D細胞培養システム:開発者の情勢

  • 章の概要
  • 全体的な市場情勢
    • 設立年別分析
    • 企業規模別分析
    • 本社所在地別分析
    • 3D細胞培養フォーマット別分析
    • 製品タイプ別分析
  • ヒートマップ表現:3D細胞培養フォーマットと本社の場所別分析
  • ツリーマップ表現:企業の規模と製品タイプ別分析
  • 世界地図での表現:地域本部の場所別分析
  • 3D細胞培養:サービスプロバイダーのリスト
  • 3D細胞培養:アッセイ、キット、試薬のリスト

第7章 市場情勢:スキャフォールド(足場)型製品

  • 章の概要
  • 総市場情勢
    • 開発状況別分析
    • 製品タイプ別分析
    • 3D培養細胞のソース別分析
    • 製造に使用された方法別分析
    • 製造に使用される材料別分析
    • 製品の種類と3D培養細胞のソース別分析
    • 製品の種類と製造に使用された方法別分析
  • 開発者情勢
    • 設立年別分析
    • 企業規模別分析
    • 本社所在地別分析
  • 主な開発者:スキャフォールドの製品数別分析
  • ツリーマップ:製品タイプと企業規模別分析

第8章 市場情勢:非スキャフォールド(足場)型製品

  • 章の概要
  • 総市場情勢
    • 開発状況別分析
    • 製品タイプ別分析
    • 3D培養細胞の原料別分析
    • 製造に使用された方法別分析
    • 製造に使用される材料別分析
    • 製品タイプと3D培養細胞の原料別分析
    • 製品タイプと製造に使用された方法別分析
  • 開発者情勢
    • 設立年別分析
    • 企業規模別分析
    • 本社所在地別分析
  • 主要な開発者:非スキャフォールド製品数別分析
  • ツリーマップ表現:製品タイプと企業規模別分析

第9章 市場情勢:バイオリアクター

  • 章の概要
  • 3Dバイオリアクター:全体的な市場情勢
    • 3Dバイオリアクターの種類別分析
    • 作業量別分析
  • 3Dバイオリアクター:開発者の情勢
    • 設立年別分析
    • 企業規模別分析
    • 本社所在地別分析
  • 主な開発者:3Dバイオリアクター件数別分析

第10章 主な用途分野

  • 章の概要
  • がん研究
  • 創薬および毒性スクリーニング
  • 幹細胞研究
  • 再生医療および組織工学
  • 3D細胞培養システム:主な用途分野別分析

第11章 企業プロファイル概要:スキャフォールド(足場)型製品(ヒドロゲル/ ECM開発者)

  • 章の概要
    • 3D Biotek
    • Advanced BioMatrix
    • Alphabioregen
    • Corning Life Sciences
    • REPROCELL

第12章 企業プロファイル概要:非スキャフォールド(足場)型製品(ORGAN-ON-CHIP開発者)

  • 章の概要
    • CN Bio Innovations
    • Emulate
    • InSphero
    • Mimetas
    • TissUse

第13章 企業プロファイル概要:3Dバイオリアクター

  • 章の概要
  • BISS TGT
  • Celartia
  • Cell Culture
  • Cesco Bioengineering
  • Flexcell International
  • PBS Biotech
  • Synthecon

第14章 資金調達と投資の分析

  • 章の概要
  • 資金の種類
  • 3D細胞培養システム:資金調達と投資分析
    • 資金調達インスタンスの数別分析
    • 投資額別分析
    • 資金調達タイプ別分析
    • 3D細胞培養フォーマット別分析
    • 製品タイプ別分析
    • 地域別分析
    • 活動的な企業:資金調達インスタンス件数別分析
    • 活動的な企業:資金調達額別分析
    • 活動的な投資家:インスタンス数別分析
  • おわりに

第15章 提携と協業

  • 章の概要
  • パートナーシップモデル
  • 3D細胞培養システム:最近の提携と協業
    • 提携の年別分析
    • 提携タイプ別分析
    • 3D細胞培養フォーマット別分析
    • 製品タイプ別分析
    • 活動的な企業:提携件数別分析
    • 地域分析
    • 大陸間および大陸内協定

第16章 特許分析

  • 章の概要
  • 範囲と調査手法
  • 3D細胞培養システム:特許分析
    • 特許の種類別分析
    • 発行年別の分析
    • 発行機関別分析
    • CPCシンボル別分析
    • 新たな重点分野
    • 主要企業:特許数別分析
  • 3D細胞培養システム:特許評価分析
  • 主要な特許:引用数別分析

第17章 市場予測

  • 章の概要
  • 予測調査手法と主要な前提条件
  • COVID-19パンデミックが世界市場に与える影響
  • 世界の3D細胞培養市場(2020-2030)
  • 事業セグメント別
    • 3D細胞培養システム
    • 3D細胞培養消耗品
    • 3D細胞培養サービス
  • 3D細胞培養フォーマット別
    • スキャフォールド型
    • 非スキャフォールド型
    • 3Dバイオリアクター
  • 製品タイプ別
    • 付着抵抗性表面
    • ヒドロゲル/ECM
    • マイクロパターン化された表面
    • マイクロキャリア
    • マイクロ流体システム
    • 固体スキャフォールド
    • 懸濁液培養システム
  • 用途分野別
    • がん調査
    • 創薬および毒性検査
    • 幹細胞研究
    • 再生医療および組織工学
  • 目的別
    • 研究用
    • 治療用
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋
    • ラテンアメリカ
    • 中東および北アフリカ
    • その他の地域
  • 主要企業別(2020)
  • おわりに

第18章 調査分析

  • 章の概要
  • 回答者の概要
  • 調査の洞察
    • 3D細胞培養フォーマット
    • 提供される製品の種類
    • 製品開発の状況
    • 3D培養細胞の材料
    • 製造に使用される方法
    • 用途の領域
    • 3D細胞培養のために提供されるサービス
    • 現在および将来の市場機会

第19章 結論

第20章 エグゼクティブインサイト

  • 章の概要
  • Cellendes
  • Synthecon
  • BRTI Life Sciences
  • Kirkstall
  • QGel
  • Xylyx Bio
  • InSphero
  • GSI
  • Nanofiber Solutions、ほか

第21章 付録I:集計データ

第22章 付録II:企業と組織のリスト

図表

List Of Tables

  • Table 3.1: Morphology of Cells in a Culture
  • Table 3.2: Differences between 2D and 3D Cell Cultures
  • Table 3.3: Features of 3D Spheroids generated via 3D Cell Culture Systems
  • Table 4.1: Advantages and Disadvantages of Scaffold Based and Scaffold Free Systems
  • Table 4.2: Advantages and Disadvantages of Natural and Synthetic Scaffolds
  • Table 4.3: Advantages and Disadvantages of Natural and Synthetic Hydrogels
  • Table 4.4: Cell Cultures Used in Magnetic Levitation
  • Table 4.5: Origin and Culture Techniques Used for Organoids
  • Table 5.1: Advantages and Disadvantages of Methods Used for Fabrication for Porous Scaffolds
  • Table 5.2: 3D Cell Culture Studies Using Porous Scaffolds
  • Table 5.3: Methods for Fabrication Used of Fibrous Scaffolds
  • Table 5.4: Advantages and Disadvantages of Methods Used for Fabrication of Fibrous Scaffolds
  • Table 5.5: 3D Cell Culture Studies Using Fibrous Scaffolds
  • Table 5.6: Advantages and Disadvantages of Methods Used for Fabrication of Hydrogels
  • Table 5.7: 3D Cell Culture Studies Using Hydrogels
  • Table 5.8: Advantages and Disadvantages of Methods Used for Fabrication of Custom Scaffolds
  • Table 5.9: 3D Cell Culture Studies Using Custom Scaffolds
  • Table 5.10: Advantages and Disadvantages of Methods Used for Fabrication of Microspheres
  • Table 5.11: 3D Cell Culture Studies Using Microspheres
  • Table 5.12: 3D Cell Culture Studies Using Native Scaffolds
  • Table 6.1: 3D Cell Culture Systems: List of Developers
  • Table 6.2: 3D Cell Culture Systems: List of Service Providers
  • Table 6.3: 3D Cell Culture Systems: List of Assays, Kits and Reagents
  • Table 7.1: Scaffold Based Products: List of Products
  • Table 7.2: Scaffold Based Products: List of Developers
  • Table 8.1: Scaffold Free Products: List of Products
  • Table 8.2: Scaffold Free Products: List of Developers
  • Table 9.1: 3D Bioreactors: List of Products
  • Table 9.2: 3D Bioreactors: List of Developers
  • Table 10.1 Scaffold Based Products: Information on Key Application Areas
  • Table 10.2 Scaffold Free Products: Information on Key Application Areas
  • Table 10.3 3D Bioreactors: Information on Key Application Areas
  • Table 11.1: Scaffold Based Products (Hydrogel / ECM): List of Companies Profiled
  • Table 11.2: 3D Biotek: Company Snapshot
  • Table 11.3: 3D Biotek: Key Characteristics of Hydrogels / ECMs
  • Table 11.4: Advanced Biomatrix: Company Snapshot
  • Table 11.5: Advanced Biomatrix: Key Characteristics of Hydrogels / ECMs
  • Table 11.6: Advanced Biomatrix: Recent Developments and Future Outlook
  • Table 11.7: Alphabioregen: Company Snapshot
  • Table 11.8: Alphabioregen: Key Characteristics of Hydrogels / ECMs
  • Table 11.9: Corning Life Sciences: Company Snapshot
  • Table 11.10: Corning Life Sciences: Key Characteristics of Hydrogels / ECMs
  • Table 11.11: Corning Life Sciences: Recent Developments and Future Outlook
  • Table 11.12: REPROCELL: Company Snapshot
  • Table 11.13: REPROCELL: Key Characteristics of Hydrogels / ECMs
  • Table 11.14: REPROCELL: Recent Developments and Future Outlook
  • Table 12.1: Scaffold Free Products (Organ-on-Chip): List of Companies Profiled
  • Table 12.2: CN Bio Innovations: Company Snapshot
  • Table 12.3: CN Bio Innovations: Information on Funding Instances
  • Table 12.4: CN Bio Innovations: Key Characteristics of Organ-on-Chips Products
  • Table 12.5: CN Bio Innovations: Recent Developments and Future Outlook
  • Table 12.6: Emulate: Company Snapshot
  • Table 12.7: Emulate: Information on Funding Instances
  • Table 12.8: Emulate: Key Characteristics of Organ-on-Chips Products
  • Table 12.9: Emulate: Recent Developments and Future Outlook
  • Table 12.10: InSphero: Company Snapshot
  • Table 12.11: InSphero: Information on Funding Instances
  • Table 12.12: InSphero: Key Characteristics of Organ-on-Chips Products
  • Table 12.13: InSphero: Recent Developments and Future Outlook
  • Table 12.14: Mimetas: Company Snapshot
  • Table 12.15: Mimetas: Information on Funding Instances
  • Table 12.16: Mimetas: Key Characteristics of Organ-on-Chips Products
  • Table 12.17: Mimetas: Recent Developments and Future Outlook
  • Table 12.18: Mimetas: Company Snapshot
  • Table 12.19: Mimetas: Information on Funding Instances
  • Table 12.20: Mimetas: Key Characteristics of Organ-on-Chips Products
  • Table 12.21: Mimetas: Recent Developments and Future Outlook
  • Table 12.22: TissUse: Company Snapshot
  • Table 12.23: TissUse: Key Characteristics of Organ-on-Chips Products
  • Table 12.24: TissUse: Recent Developments and Future Outlook
  • Table 13.1: 3D Bioreactors: List of Companies Profiled
  • Table 13.2: BISS TGT: Company Snapshot
  • Table 13.3: BISS TGT: Key Characteristics of 3D Bioreactors
  • Table 13.4: BISS TGT: Recent Developments and Future Outlook
  • Table 13.5: Celartia: Company Snapshot
  • Table 13.6: Celartia: Key Characteristics of 3D Bioreactors
  • Table 13.7: Cell Culture: Company Snapshot
  • Table 13.8: Cell Culture: Key Characteristics of 3D Bioreactors
  • Table 13.9: CESCO Bioengineering: Company Snapshot
  • Table 13.10: CESCO Bioengineering: Key Characteristics of 3D Bioreactors
  • Table 13.11: EBERS: Company Snapshot
  • Table 13.12: EBERS: Key Characteristics of 3D Bioreactors
  • Table 13.13: EBERS: Recent Developments and Future Outlook
  • Table 13.14: Flexcell International: Company Snapshot
  • Table 13.15: Flexcell International: Key Characteristics of 3D Bioreactors
  • Table 13.16: PBS Biotech: Company Snapshot
  • Table 13.17: PBS Biotech: Key Characteristics of 3D Bioreactors
  • Table 13.18: Synthecon: Company Snapshot
  • Table 13.19: Synthecon: Key Characteristics of 3D Bioreactors
  • Table 14.1: Funding and Investments: Information on Year of Investment, Type of Funding, Amount Raised and Investor, 2015 - Q3 2020
  • Table 14.2: Funding and Investments: Information on Year of Establishment, Location of Headquarters of Recipients, Focus Area, and Type of Product, 2015 - Q3 2020
  • Table 15.1: Partnerships and Collaborations: Information on Year of Agreement, Type of Partnership Model, and Partner, 2015 - Q3 2020
  • Table 15.2: Partnerships and Collaborations: Information on Type of Agreement, Focus Area, and Type of Product, 2015 - Q3 2020
  • Table 16.1: Patent Analysis: CPC Symbols
  • Table 16.2: Patent Analysis: Most Popular CPC Symbols
  • Table 16.3: Patent Analysis: List of Top 10 CPC Symbols
  • Table 16.4: Patent Analysis: List of Relatively High Value Patents
  • Table 17.1: Global 3D Cell Culture Systems Market: Key Assumptions Related to Distribution by Type of Products
  • Table 18.1: Survey Insights: Overview of Respondents
  • Table 18.2: Survey Insights: Designation and Seniority Level
  • Table 18.3: Survey Insights: Focus Area of the Company
  • Table 18.4: Survey Insights: Type of 3D Cell Culture Products Offered
  • Table 18.5: Survey Insights: Status of Development of Product(s)
  • Table 18.6: Survey Insights: Method of Fabrication Used
  • Table 18.7: Survey Insights: Source of 3D Cultured Cells
  • Table 18.8: Survey Insights: Key Areas of Application
  • Table 18.9: Survey Insights: 3D Cell Culture Services Offered
  • Table 18.10: Survey Insights: Current Market Opportunity (2020)
  • Table 18.11: Survey Insights: Future Market Opportunity (2030)
  • Table 20.1: Cellendes: Company Snapshot
  • Table 20.2: Synthecon: Company Snapshot
  • Table 20.3: BRTI Life Sciences: Company Snapshot
  • Table 20.4: Kirkstall: Company Snapshot
  • Table 20.5: QGel: Company Snapshot
  • Table 20.6: Xylyx Bio: Company Snapshot
  • Table 20.7: InSphero: Company Snapshot
  • Table 20.8: GSI: Company Snapshot
  • Table 20.9: Nanofiber Solutions: Company Snapshot
  • Table 21.1: 3D Cell Culture 7System Developers: Distribution by Year of Establishment
  • Table 21.2: 3D Cell Culture System Developers: Distribution by Company Size
  • Table 21.3: 3D Cell Culture System Developers: Distribution by Location of Headquarters
  • Table 21.4: 3D Cell Culture System Developers: Distribution by 3D Cell Culture Format
  • Table 21.5: 3D Cell Culture System Developers: Distribution by Type of Product
  • Table 21.6: 3D Cell Culture System Developers: Distribution by Number of Products
  • Table 21.7: Heat Map Representation: Distribution by 3D Cell Culture Format and Location of Headquarters
  • Table 21.8: Tree Map Representation: Distribution by Company Size and Type of Product
  • Table 21.9: World Map Representation: Distribution by Location of Regional Headquarters
  • Table 21.10: Scaffold Based Products: Distribution by Status of Development
  • Table 21.11: Scaffold Based Products: Distribution by Type of Product
  • Table 21.12: Scaffold Based Products: Distribution by Source of 3D Cultured Cells
  • Table 21.13: Scaffold Based Products: Distribution by Method Used for Fabrication
  • Table 21.14: Scaffold Based Products: Distribution by Material Used for Fabrication
  • Table 21.15: Scaffold Based Products: Distribution by Type of Product and Source of 3D Cultured Cells
  • Table 21.16: Scaffold Based Products: Distribution by Type of Product and Method Used for Fabrication
  • Table 21.17: Scaffold Based Product Developers: Distribution by Year of Establishment
  • Table 21.18: Scaffold Based Product Developers: Distribution by Company Size
  • Table 21.19: Scaffold Based Product Developers: Distribution by Location of Headquarters
  • Table 21.20: Leading Developers: Distribution by Number of Scaffold Based Products
  • Table 21.21: Tree Map Representation: Distribution by Type of Product and Company Size
  • Table 21.22: Scaffold Free Products: Distribution by Status of Development
  • Table 21.23: Scaffold Free Products: Distribution by Type of Product
  • Table 21.24: Scaffold Free Products: Distribution by Source of 3D Cultured Cells
  • Table 21.25: Scaffold Free Products: Distribution by Method Used for Fabrication
  • Table 21.26: Scaffold Free Products: Distribution by Material Used for Fabrication
  • Table 21.27: Scaffold Free Products: Distribution by Type of Product and Source of 3D Cultured Cells
  • Table 21.28: Scaffold Free Products: Distribution by Type of Product and Method Used for Fabrication
  • Table 21.29: Scaffold Free Product Developers: Distribution by Year of Establishment
  • Table 21.30: Scaffold Free Product Developers: Distribution by Company Size
  • Table 21.31: Scaffold Free Product Developers: Distribution by Location of Headquarters
  • Table 21.32: Leading Developers: Distribution by Number of Scaffold Free Products
  • Table 21.33: Tree Map Representation: Distribution by Type of Product and Company Size
  • Table 21.34: 3D Bioreactors: Distribution by Type of 3D Bioreactor
  • Table 21.35: 3D Bioreactors: Distribution by Working Volume
  • Table 21.36: 3D Bioreactor Developers: Distribution by Year of Establishment
  • Table 21.37: 3D Bioreactor Developers: Distribution by Company Size
  • Table 21.38: 3D Bioreactor Developers: Distribution by Location of Headquarters
  • Table 21.39: Leading Developers: Distribution by Number of 3D Bioreactors
  • Table 21.40: 3D Cell Culture Systems: Distribution by Key Application Areas
  • Table 21.41: 3D Cell Culture Systems: Distribution by Key Application Areas and 3D Cell Culture Format
  • Table 21.42: Scaffold Based Products: Distribution by Key Application Areas
  • Table 21.43: Scaffold Free Products: Distribution by Key Application Areas
  • Table 21.44: 3D Bioreactors: Distribution by Key Application Areas
  • Table 21.45: Funding and Investments: Distribution of Recipient Companies by Year of Establishment and Type of Funding, 2015-Q3 2020
  • Table 21.46: Funding and Investments: Cumulative Number of Instances by Year, 2015-Q3 2020
  • Table 21.47: Funding and Investments: Cumulative Amount Invested, 2015-Q3 2020 (USD Million)
  • Table 21.48: Funding and Investments: Distribution of Instances by Type of Funding, 2015-Q3 2020
  • Table 21.49: Funding and Investments: Year-Wise Distribution by Number of Instances and Type of Funding, 2015 - Q3 2020
  • Table 21.50: Funding and Investments: Distribution of Amount Invested by Type of Funding, 2015 - Q3 2020 (USD Million)
  • Table 21.51: Funding and Investments: Year-Wise Distribution of Amount Invested and Type of Funding, 2015 - Q3 2020
  • Table 21.52: Funding and Investments: Distribution of Instances and Amount Invested by 3D Cell Culture Format, 2015-Q3 2020
  • Table 21.53: Funding and Investments: Distribution of Instances and Amount Invested by Type of Product, 2015-Q3 2020
  • Table 21.54: Funding and Investments: Distribution by Geography
  • Table 21.55: Funding and Investments: Regional Distribution by Total Amount Invested, 2015-Q3 2020
  • Table 21.56: Most Active Players: Distribution by Number of Funding Instances, 2015-Q3 2020
  • Table 21.57: Most Active Players: Distribution by Amount Raised, 2015-Q3 2020 (USD Million)
  • Table 21.58: Most Active Investors: Distribution by Funding Instances, 2015-Q3 2020
  • Table 21.59: Partnerships and Collaborations: Cumulative Year-Wise Trend, 2015-Q3 2020
  • Table 21.60: Partnerships and Collaborations: Distribution by Type of Partnership
  • Table 21.61: Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partnership
  • Table 21.62: Partnerships and Collaborations: Distribution by Company Size and Type of Partnership
  • Table 21.63: Partnerships and Collaborations: Distribution by Type of Partner
  • Table 21.64: Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner
  • Table 21.65: Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
  • Table 21.66: Partnerships and Collaborations: Distribution by 3D Cell Culture Format
  • Table 21.67: Partnerships and Collaborations: Distribution by Year of Partnership and 3D Cell Culture Format
  • Table 21.68: Partnerships and Collaborations: Distribution by Type of Partnership and 3D Cell Culture Format
  • Table 21.69: Partnerships and Collaborations: Distribution by Type of Product
  • Table 21.70: Partnerships and Collaborations: Distribution by Year of Partnership and Type of Product
  • Table 21.71: Partnerships and Collaborations: Distribution by Type of Partnership and Type of Product
  • Table 21.72: Most Active Players: Distribution by Number of Partnerships
  • Table 21.73: Partnerships and Collaborations: Regional Distribution
  • Table 21.74: Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
  • Table 21.75: Patent Analysis: Distribution by Type of Patent
  • Table 21.76: Patent Analysis: Cumulative Distribution by Publication Year, 2015-Q3 2020
  • Table 21.77: Patent Analysis: Distribution of Granted Patents by Publication Year, 2015-Q3 2020
  • Table 21.78: Patent Analysis: Distribution of Filed Patents Publication Year, 2015-Q3 2020
  • Table 21.79: Patent Analysis: Distribution by Number of Patent Type and Publication Year, 2015-Q3 2020
  • Table 21.80: Patent Analysis: Distribution by Issuing Authorities Involved
  • Table 21.81: Patent Analysis: Cumulative Year-wise Distribution by Type of Applicant, 2015-Q3 2020
  • Table 21.82: Leading Patent Assignees (Industry Players): Distribution by Number of Patents
  • Table 21.83: Leading Patent Assignees (Non-Industry Players): Distribution by Number of Patents
  • Table 21.84: Patent Analysis: Distribution by Patent Age, 2000-2020
  • Table 21.85: Patent Analysis: Valuation Analysis
  • Table 21.86: Global 3D Cell Culture Market, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
  • Table 21.87: Global 3D Cell Culture Market: Distribution by Business Segment, 2020 and 2030
  • Table 21.88: 3D Cell Culture Systems Market, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
  • Table 21.89: 3D Cell Culture Consumables Market, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
  • Table 21.90: 3D Cell Culture Services Market, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
  • Table 21.91: Global 3D Cell Culture Systems Market: Distribution by 3D Cell Culture Format, 2020 and 2030
  • Table 21.92: 3D Cell Culture Systems Market for Scaffold based Products, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
  • Table 21.93: 3D Cell Culture Systems Market for Scaffold Free Products, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
  • Table 21.94: 3D Cell Culture Systems Market for Market 3D Bioreactors, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
  • Table 21.95: Global 3D Cell Culture Systems Market: Distribution by Type of Product, 2020 and 2030
  • Table 21.96: 3D Cell Culture Systems Market for Attachment Resistant Surfaces, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
  • Table 21.97: 3D Cell Culture Systems Market for Hydrogels / ECMs, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
  • Table 21.98: 3D Cell Culture Systems Market for Micropatterned Surface, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
  • Table 21.99: 3D Cell Culture Systems Market for Microcarriers, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
  • Table 21.100: 3D Cell Culture Systems Market for Microfluidic Systems, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
  • Table 21.101: 3D Cell Culture Systems Market for Solid Scaffolds, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
  • Table 21.102: 3D Cell Culture Systems Market for Suspension Culture Systems, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
  • Table 21.103: Global 3D Cell Culture Systems Market: Distribution by Area of Application, 2020 and 2030
  • Table 21.104: 3D Cell Culture Systems Market for Cancer Research, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
  • Table 21.105: 3D Cell Culture Systems Market for Drug Discovery and Toxicity Testing, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
  • Table 21.106: 3D Cell Culture Systems Market for Stem Cell Research, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
  • Table 21.107: 3D Cell Culture Systems Market for Regenerative Medicine and Tissue Engineering, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
  • Table 21.108: Global 3D Cell Culture Systems Market: Distribution by Purpose, 2020 and 2030
  • Table 21.109: 3D Cell Culture Systems Market for Research Use, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
  • Table 21.110: 3D Cell Culture Systems Market for Therapeutic Use, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
  • Table 21.111: Global 3D Cell Culture Systems Market: Distribution by Geography, 2020 and 2030
  • Table 21.112: 3D Cell Culture Systems Market in North America, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
  • Table 21.113: 3D Cell Culture Systems Market in Europe, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
  • Table 21.114: 3D Cell Culture Systems Market in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
  • Table 21.115: 3D Cell Culture Systems Market in Latin America, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
  • Table 21.116: 3D Cell Culture Systems Market in Middle East and North Africa (MENA), Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
  • Table 21.117: 3D Cell Culture Systems Market in Rest of the World, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
  • Table 21.118: Global 3D Cell Culture Systems Market: Distribution by Leading Players, 2020
  • Table 21.119: Global 3D Cell Culture Systems Market: Conservative, Base and Optimistic Scenarios, 2020, 2025 and 2030 (USD Million)
  • Table 21.120: Survey Insights: Distribution of Respondents by Year of Establishment of Company
  • Table 21.121: Survey Insights: Distribution of Respondents by Company Size
  • Table 21.122: Survey Insights: Distribution of Respondents by Location of Company Headquarters (Region-Wise)
  • Table 21.123: Survey Insights: Distribution of Respondents by Location of Company Headquarters (Country-Wise)
  • Table 21.124: Survey Insights: Distribution of Respondents by Designation and Seniority Level
  • Table 21.125: Survey Insights: Distribution by Focus Area
  • Table 21.126: Survey Insights: Distribution by Type of 3D Cell Culture Products Offered
  • Table 21.127: Survey Insights: Distribution by Development Status of Product(s)
  • Table 21.128: Survey Insights: Distribution by Method of Fabrication Used
  • Table 21.129: Survey Insights: Distribution by Source of Cultured Cells
  • Table 21.130: Survey Insights: Distribution by Key Application Areas
  • Table 21.131: Survey Insights: Distribution by 3D Cell Culture Services Offered
  • Table 21.132: Survey Insights: Distribution by Current and Future Market Opportunity, 2020 and 2030

List Of Company

The following companies / organizations have been mentioned in this report.

  • 1. 101Bio
  • 2. 3D Biomatrix
  • 3. 3D Biotek
  • 4. 3D Biotechnology Solutions
  • 5. 3Dnamics
  • 6. 4Dcell
  • 7. 4titude
  • 8. AbbVie Ventures
  • 9. abc biopply
  • 10. ABL Europe
  • 11. Abo Akademi University
  • 12. Abstraction Ventures
  • 13. Abzena
  • 14. Accellta
  • 15. Advanced BioMatrix
  • 16. Advanced Regenerative Manufacturing Institute (ARMI)
  • 17. Advanced Scientifics
  • 18. Aetos Biologics
  • 19. Afirmus Biosource
  • 20. AGC
  • 21. Agency for Science, Technology and Research (A*STAR)
  • 22. AIM Biotech
  • 23. Akero Therapeutics
  • 24. Akron Biotech
  • 25. Alector
  • 26. Allevi
  • 27. Alnylam Pharmaceuticals
  • 28. American Laboratory Products
  • 29. Alphabioregen
  • 30. ALS Investment Fund
  • 31. AlveoliX
  • 32. AMS Biotechnology
  • 33. AnaPath Services
  • 34. Angel Investors
  • 35. AngelMD
  • 36. Angels 5K
  • 37. Angels in MedCity
  • 38. Angels Santé
  • 39. Anthrogenesis
  • 40. Aquitaine Science Transfert
  • 41. Aquiti Gestion
  • 42. AR Brown
  • 43. ARL Design
  • 44. ARTeSYN Biosolutions
  • 45. AstraZeneca
  • 46. Arizona State University
  • 47. ATEL Ventures
  • 48. Atera
  • 49. Avantor
  • 50. AxoSim
  • 51. AXT
  • 52. Axxicon
  • 53. BASF
  • 54. Bayer
  • 55. B-CULTURE
  • 56. BEOnChip
  • 57. Bio-Byblos Biomedical
  • 58. BioCat
  • 59. BioConcept
  • 60. BIOFABICS
  • 61. Biogelx
  • 62. Bioinspired Solutions
  • 63. BioInvent International
  • 64. BIOKE
  • 65. BioLamina
  • 66. Biomaterials USA
  • 67. Biomerix
  • 68. BiomimX
  • 69. Biopredic International
  • 70. BioTek Instruments
  • 71. BiSS TGT
  • 72. Bonus BioGroup
  • 73. Bpifrance
  • 74. BRAIN
  • 75. BrainXell
  • 76. Brammer Bio
  • 77. Braveheart Investment Group
  • 78. Bristol-Myers Squibb
  • 79. Broad Institute
  • 80. BRTI Life Sciences
  • 81. Cambridge Bioscience
  • 82. University of Cambridge
  • 83. CarThera
  • 84. Cedars-Sinai Medical Center
  • 85. Celartia
  • 86. Cell Applications
  • 87. Cell Culture
  • 88. CELLEC BIOTEK
  • 89. Cellendes
  • 90. Cellevate
  • 91. CELLnTEC
  • 92. CellSpring
  • 93. CellSystems
  • 94. CelVivo
  • 95. Center for the Advancement of Science in Space
  • 96. CESCO Bioengineering
  • 97. Charles River Laboratories
  • 98. Cherry Biotech
  • 99. China Regenerative Medicine International
  • 100. CITIC Securities
  • 101. CN Bio Innovations
  • 102. CN Innovations
  • 103. Collagen Solutions
  • 104. Comune di Milano
  • 105. Corning Life Sciences
  • 106. Cosmo Bio
  • 107. CELLphenomics
  • 108. Commonwealth Serum Laboratories
  • 109. Curi Bio
  • 110. Cyprio
  • 111. Cyprotex
  • 112. Cytiva
  • 113. Danaher
  • 114. Deepbridge Capital
  • 115. Demcon
  • 116. United States Department of Defense
  • 117. Development Bank of Wales
  • 118. DiPole Materials
  • 119. Downing Ventures
  • 120. Government of the Netherlands
  • 121. Executive Agency for Small and Medium-sized Enterprises (EASME)
  • 122. EBERS
  • 123. Ectica Technologies
  • 124. EDITHGEN
  • 125. Electrospinning
  • 126. Emulate
  • 127. Enso Discoveries
  • 128. Eppendorf
  • 129. Esco Aster
  • 130. Esperante
  • 131. Ethicon
  • 132. European Life Sciences Growth Fund (ELSGF)
  • 133. European Commission
  • 134. European Union
  • 135. Eurostars
  • 136. EU-ToxRisk
  • 137. Eva Scientific
  • 138. Evotec
  • 139. faCellitate
  • 140. Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
  • 141. Fennik Life Sciences
  • 142. Ferentis
  • 143. FHNW University
  • 144. FiberCell Systems
  • 145. Fibralign
  • 146. Finep
  • 147. Finesse Solutions
  • 148. Finovam Gestion
  • 149. Flexcell International
  • 150. Foundation for Technological Innovation
  • 151. Founder
  • 152. Founders Fund
  • 153. Freeline
  • 154. French Government
  • 155. Frequency Therapeutics
  • 156. FroggaBio
  • 157. Fujifilm
  • 158. FUJIFILM Wako Pure Chemical
  • 159. Funakoshi
  • 160. Gabriel Investments
  • 161. Galapagos
  • 162. GALIA Gestion
  • 163. Gamma 3
  • 164. Gelmetix
  • 165. Gelomics
  • 166. Gemini Bio
  • 167. Gemstone Biotherapeutics
  • 168. Genome Institute of Singapore
  • 169. Georgia Research Alliance
  • 170. Global Cell Solutions
  • 171. Government of China
  • 172. Great Stuff Ventures
  • 173. GSI
  • 174. GlaxoSmithKline
  • 175. HµREL
  • 176. Hamilton
  • 177. Harvard Apparatus
  • 178. Harvard College
  • 179. HCS Pharma
  • 180. Helvoet
  • 181. Heraeus Medical
  • 182. Hesperos
  • 183. Histogenics
  • 184. Human Models for Analysis of Pathways (HMAPs) Center
  • 185. Hokkaido Soda
  • 186. HP Wild Holding
  • 187. Hubrecht Organoid Technology
  • 188. Humanetics
  • 189. Hyamedix
  • 190. ibidi
  • 191. IMSS-Gulf Bio Analytical
  • 192. INITIO CELL
  • 193. Innovate UK
  • 194. Innovation Fund Denmark
  • 195. Inova Health System
  • 196. inRegen
  • 197. InSphero
  • 198. Invitrocue
  • 199. InvivoSciences
  • 200. Ionis Pharmaceuticals
  • 201. Irdi Soridec Gestion
  • 202. Janssen Biotech
  • 203. Japan Vilene Company
  • 204. Jellagen Marine Biotechnologies
  • 205. Johns Hopkins University
  • 206. JRI Orthopaedics
  • 207. Kero
  • 208. Kim & Friends
  • 209. Kirkstall
  • 210. KIYATEC
  • 211. KOKEN
  • 212. Koninklijke Nederlandse Akademie Van Wetenschappen
  • 213. Kuraray
  • 214. LabCorp
  • 215. Laconia
  • 216. LAMBDA Laboratory Instruments
  • 217. Lantern Pharma
  • 218. Lawrence J. Ellison Institute for Transformative Medicine
  • 219. LBA Healthcare Management
  • 220. Lena Biosciences
  • 221. LFB Biomanufacturing
  • 222. Life Technologies
  • 223. Lifecore Biomedical
  • 224. LifeNet Health
  • 225. Laboratory for Integrated Micro Mechatronic Systems
  • 226. Lineage Cell Therapeutics
  • 227. Locate Bio
  • 228. London School of Hygiene & Tropical Medicine
  • 229. Lonza
  • 230. Lund University
  • 231. LuoLabs
  • 232. Manchester BIOGEL
  • 233. University of Mannheim
  • 234. Maryland Momentum Fund
  • 235. Massachusetts Institute of Technology
  • 236. MassChallenge
  • 237. MatTek Life Sciences
  • 238. MBL International
  • 239. GlassWall Syndicate
  • 240. Menicon Life Science
  • 241. Merck Accelerator
  • 242. Merck Millipore
  • 243. Michael J. Fox Foundation
  • 244. Michigan Technological University
  • 245. Micronit
  • 246. MicroTissues
  • 247. Midven
  • 248. MIMETAS
  • 249. Minerva Business Angel Network
  • 250. Molecular Devices
  • 251. Maryland Stem Cell Research Fund (MSCRF)
  • 252. MTTlab
  • 253. Nanobiose
  • 254. Nano Dimension
  • 255. Nanofiber Solutions
  • 256. Nanogaia
  • 257. National Aeronautics and Space Administration
  • 258. National Center for Advancing Translational Sciences
  • 259. National Institute of Health
  • 260. National Institute on Aging
  • 261. National Institutes for Food and Drug Control
  • 262. National Science Foundation
  • 263. National University Hospital
  • 264. National University of Singapore
  • 265. National Centre for the Replacement, Refinement and Reduction of Animals in Research
  • 266. Neuromics
  • 267. New Orleans BioFund
  • 268. Newable Private Investing
  • 269. Nexcelom Bioscience
  • 270. Nord France Amorquage
  • 271. Invest Northern Ireland
  • 272. Northwick Park Institute for Medical Research
  • 273. Nortis
  • 274. Nova Biomedical
  • 275. Novartis Venture Fund
  • 276. Noviocell
  • 277. Nucleus Biologics
  • 278. NYU Winthrop Hospital
  • 279. Olaregen Therapeutix
  • 280. OMNI Life Science
  • 281. Oregon Health & Science University
  • 282. Organovo
  • 283. Orthomimetics
  • 284. OS Fund
  • 285. Oxford MEStar
  • 286. Pairnomix
  • 287. Pall Corporation
  • 288. Path BioAnalytics
  • 289. PBS Biotech
  • 290. Peak Capital Advisors
  • 291. Pelo Biotech
  • 292. Pensees
  • 293. PepGel
  • 294. Percell Biolytica
  • 295. PerkinElmer
  • 296. Pfizer
  • 297. PHI
  • 298. Pitch@Palace
  • 299. PL BioScience
  • 300. Plasticell
  • 301. Pluristem Therapeutics
  • 302. Portugal Ventures
  • 303. Precision Biologics
  • 304. Premedical Laboratories
  • 305. Primorigen Biosciences
  • 306. Principia SGR
  • 307. ProBio
  • 308. ProBioGen
  • 309. Prodizen
  • 310. PromoCell
  • 311. Protista International
  • 312. QGel Bio
  • 313. QIAGEN (Suzhou)
  • 314. Quintech Life Sciences
  • 315. PT Rajawali Medika Mandiri
  • 316. RASA
  • 317. React4life
  • 318. Real Research
  • 319. RealBio Technology
  • 320. Regemat3D
  • 321. Repligen
  • 322. REPROCELL
  • 323. Research Without Animal Experiment
  • 324. Revivocell
  • 325. Rigenerand
  • 326. Roche
  • 327. RoosterBio
  • 328. Roswell Park Comprehensive Cancer Center
  • 329. Sanofi Ventures
  • 330. SARSTEDT
  • 331. Sartorius
  • 332. S-BIO
  • 333. ScienCell
  • 334. SciFi VC
  • 335. SciKon Innovation
  • 336. Scinus Cell Expansion
  • 337. Scottish Investment Bank
  • 338. Seres Therapeutics
  • 339. Shanghai Cienle Medical Technology
  • 340. Shanghai Institute of Materia Medica
  • 341. Shanghai Institute of Biochemistry and Cell Biology
  • 342. Siemens Technology
  • 343. Sigma-Aldrich
  • 344. SKE Research Equipment
  • 345. SmiLe Incubator
  • 346. SoloHill Engineering
  • 347. Spheritech
  • 348. Spiber Technologies
  • 349. Start-Up Chile
  • 350. State Key Laboratory of Experimental Hematology
  • 351. StemCell Systems
  • 352. STEMCELL Technologies
  • 353. Stemmatters
  • 354. StemoniX
  • 355. StemTek Therapeutics
  • 356. SUN bioscience
  • 357. Commission for Technology and Innovation
  • 358. Swiss Federal Laboratories for Materials Science and Technology
  • 359. SyndicateRoom
  • 360. Synthecon
  • 361. SynVivo
  • 362. TA Instruments
  • 363. Takeda
  • 364. Tantti Laboratory
  • 365. tebu-bio
  • 366. TEDCO
  • 367. Terumo
  • 368. Texas Tech University Health Sciences Center
  • 369. Development Bank of Wales
  • 370. Ministry of Higher Education, Research and Innovation (France)
  • 371. The Idea Village
  • 372. Institute for Molecular Medicine Finland
  • 373. Mario Negri Institute for Pharmacological Research
  • 374. University of Alberta
  • 375. University of Bath
  • 376. University of Brescia
  • 377. University of Bristol
  • 378. University of Manchester
  • 379. University of Milan
  • 380. University of Strathclyde
  • 381. University of Zurich
  • 382. TheWell Bioscience
  • 383. Thermo Fisher Scientific
  • 384. Tianjin Weikai Biological Engineering
  • 385. Tissue Click
  • 386. TissueLabs
  • 387. TissUse
  • 388. Tokyo Future Style
  • 389. TPG
  • 390. TreeFrog Therapeutics
  • 391. Trevigen
  • 392. Triumvirate Environmental
  • 393. Technical University of Berlin
  • 394. Twinhelix
  • 395. UK Innovation & Science Seed Fund
  • 396. Science and Technology Facilities Council (STFC)
  • 397. UK Science and Technology Facilities Council
  • 398. University of Genoa
  • 399. University College London
  • 400. University Hospital Zurich
  • 401. Stanford University
  • 402. University of Arkansas for Medical Sciences
  • 403. University of California
  • 404. University of Central Florida
  • 405. University of Nottingham
  • 406. The University of Sheffield
  • 407. University of Washington School of Pharmacy
  • 408. University of Zurich
  • 409. UPM Biomedicals
  • 410. U.S. Small Business Administration
  • 411. UW Medicine
  • 412. VA Portland Health Care System
  • 413. Vanderbilt University
  • 414. Venture Kick
  • 415. VentureSouth
  • 416. Venturecraft
  • 417. Viscofan BioEngineering
  • 418. Visikol
  • 419. Vivo Biosciences
  • 420. VWR
  • 421. Wake Forest Institute for Regenerative Medicine
  • 422. Women Who Tech
  • 423. XAnge
  • 424. Xenos
  • 425. XP Biomed
  • 426. Xylyx Bio
  • 427. Zhejiang University
  • 428. zPREDICTA
目次

Title:
3D Cell Culture Market
by Scaffold Format (Scaffold Based / Scaffold Free System), Products (Hydrogel / Extracellular Matrix (ECM), 3D Bioreactor, 3D Petri Dish, Microfluidic System, Microcarrier, Organ-on-Chip and Others), Application Areas (Cancer Research, Drug Discovery and Toxicology, Stem Cell Research, Tissue Engineering and Regenerative Medicine), Purpose (Research Use and Therapeutic Use), and Key Geographical Regions: Industry Trends and Global Forecasts (3rd Edition), 2020-2030.

Overview:

Animal cell cultures represent an integral part of the drug discovery and development process. The conventional 2 dimensional (2D) cell culturing format is still extensively used in early stage research and is instrumental in establishing initial proof-of-concept and validating mechanisms of action of pharmacological leads. However, over time, it has been demonstrated that such cultures are unable to accurately mimic the natural (in vivo) microenvironment. Moreover, cells cultured in monolayers are both morphologically and physiochemically different from their in vivo counterparts. This leads to differences in viability, growth rate, and function. Additionally, in adherent 2D culture systems, only 50% of the cell surface is exposed to the culture medium, which limits cell-to-cell and cell-to-medium interactions. In fact, a study reported that 95% of drugs that exhibited efficacy in 2D culture models failed in in vivo studies / human trials.

Advances in biotechnology and materials science have enabled the development of a variety of 3-dimensional (3D) cell culture models. These systems have been demonstrated to be capable of more accurately simulating the natural tissue microenvironment and, thereby, can help overcome most of the challenges associated with 2D systems. In addition, there are certain complex 3D cell culture models that are likely to soon replace animal models. In other words, 3D cell cultures are able to better simulate the natural tissue microenvironments, thereby, serving as better in vivo models for use in experimental research, including drug discovery / toxicity testing, development of regenerative medicine, tissue engineering, and stem cell research . This is anticipated to drive the adoption of such solutions in the foreseen future. Moreover, in a recent study, perfused 3D culture systems were used to emulate human bronchial tissue and airway cells, in order to study infectious respiratory diseases . Further, 3D cell cultures and organoid-based screening systems are being developed to facilitate the study of the pathogenesis of the novel coronavirus and support ongoing drug development efforts on this front. Based on the current trend of use, we are led to believe that the COVID-19 pandemic is likely to result in an increased demand for such solutions, presenting lucrative opportunities for companies engaged in this domain. In this context, the overall 3D cell culture market is anticipated to witness substantial growth in the coming years.

Scope of the Report:

The "3D Cell Culture Market by Scaffold Format (Scaffold Based and Scaffold Free System), Products (Hydrogel / Extracellular Matrix (ECM), 3D Bioreactor, 3D Petri Dish, Hanging Drop Plate, Microfluidic System, Micropatterned Surface, Microcarrier, Organ-on-Chip, Solid Scaffold, and Suspension System), Application Areas (Cancer Research, Drug Discovery and Toxicology, Stem Cell Research, Tissue Engineering and Regenerative Medicine), Purpose (Research Use and Therapeutic Use), and Key Geographical Regions (North America, Europe, Asia-Pacific, Latin America, MENA and Rest of the World): Industry Trends and Global Forecasts (3rd Edition), 2020-2030" report features an extensive study of the current landscape and the likely future potential of 3D culture systems, over the next decade. The study also features an in-depth analysis, highlighting the capabilities of various industry stakeholders engaged in this field. In addition to other elements, the study includes:

  • An insightful assessment of the current market landscape of companies offering various 3D cell culture systems, along with information on a number of relevant parameters, such as year of establishment, size of employee base, geographical presence, 3D cell culture format (scaffold based products, scaffold free products and 3D bioreactors), and type of product (hydrogels / ECMs, micropatterned surfaces, solid scaffolds, microcarriers, attachment resistant surfaces, suspension systems and microfluidic systems). In addition, the chapter provides information related to the companies providing 3D culture related services, and associated reagents / consumables.
  • A detailed assessment of the overall landscape of scaffold based products, along with information on a number of relevant parameters, such as status of development (under development, developed not commercialized, and commercialized), type of product (hydrogels / ECMs, micropatterned surfaces, solid scaffolds, and microcarriers), source of 3D cultured cells (natural and synthetic), method used for fabrication (human based, animal based, plant based, and polymer based), and material used for fabrication. In addition, it presents details of the companies developing scaffold based products, highlighting year of establishment, size of employee base, and geographical presence.
  • A detailed assessment of the overall landscape of scaffold free products, along with information on a number of relevant parameters, such as status of development (under development, developed and not commercialized, and commercialized), type of product (attachment resistant surfaces, suspension systems and microfluidic systems), source of 3D cultured cells (natural and synthetic), method used for fabrication (human based, animal based, plant based and polymer based), and material used for fabrication. In addition, it presents details of the companies developing scaffold free products, highlighting their year of establishment, size of employee base, and geographical presence.
  • A detailed assessment of the overall landscape of 3D bioreactors, along with information on a number of relevant parameters, such as type of 3D bioreactor (single-use, perfusion, fed-batch, and fixed-bed), and typical working volume. In addition, it presents details of the companies developing 3D bioreactors, highlighting year of establishment, size of employee base, and geographical presence.
  • An insightful analysis, highlighting the applications (cancer research, drug discovery and toxicology, stem cell research, tissue engineering and regenerative medicine) for which various 3D cell culture products are being developed / used.
  • Elaborate profiles of prominent players (shortlisted based on number of products being offered) that are engaged in the development of 3D cell culture products. Each company profile features a brief overview of the company, along with information on year of establishment, number of employees, location of headquarters and key members of the executive team, details of their respective product portfolio, recent developments, and an informed future outlook.
  • An analysis of the investments made in the period between 2015 and 2020, including seed financing, venture capital financing, debt financing, grants / awards, capital raised from IPOs and subsequent offerings, at various stages of development in small and mid-sized companies (established after 2005; with less than 200 employees) that are engaged in the development of 3D cell culture products.
  • An analysis of the various partnerships related to 3D cell culture products, which have been established between 2015 and 2020 (till September), based on several parameters, such as year of agreement, type of partnership (product development / commercialization agreements, product integration / utilization agreements, product licensing agreement, research and development agreements, distribution agreements, acquisitions, joint venture and other agreements), 3D cell culture format (scaffold based products, scaffold free products and 3D bioreactor), type of product (hydrogels / ECMs, micropatterned surfaces, solid scaffolds, microcarriers, attachment resistant surfaces, suspension systems and microfluidic systems), and most active players. It also provides the regional distribution of players involved in the collaborations.
  • An in-depth analysis of over 8,400 patents that have been filed / granted for 3D cell culture products, between 2015 and 2020, highlighting key trends associated with these patents, across type of patent, publication year, issuing authorities involved, CPC symbols, emerging focus areas, leading patent assignees (in terms of number of patents filed / granted), patent characteristics and geography. It also includes a detailed patent valuation analysis.
  • An in-depth discussion on the classification of 3D cell culture systems, categorized as scaffold based systems (hydrogels / ECMs, solid scaffolds, micropatterned surfaces and microcarriers), scaffold free systems (attachment resistant surfaces, suspension systems and microfluidic systems) and 3D bioreactors.
  • An elaborate discussion on the methods used for fabrication of 3D matrices and scaffolds, highlighting the materials used, the process of fabrication, merits and demerits, and the applications of different fabrication methods.
  • Insights from an industry-wide survey, featuring inputs solicited from various experts who are directly / indirectly involved in the development of 3D cell culture products.

One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the 3D cell culture market. Based on multiple parameters, such as business segment, price of 3D cell culture products, and likely adoption of the 3D cell culture products, we have provided informed estimates on the likely evolution of the 3D cell culture systems market in the mid to long term, for the time period 2020-2030. Our year-wise projections of the current and future opportunity have further been segmented on the basis of [A] 3D cell culture scaffold (scaffold based systems, scaffold free systems, and 3D bioreactors), [B] type of product (hydrogels / ECMs, micropatterned surfaces, solid scaffolds, microcarriers, attachment resistant surfaces, suspension systems, and microfluidic systems), [C] area of application (cancer research, drug discovery / toxicity testing, stem cell research, and regenerative medicine / tissue engineering), [D] purpose (research use and therapeutic use), [E] key geographical regions (North America, Europe, Asia-Pacific, Latin America, MENA (Middle East and North Africa) and RoW (Rest of the World)), and [F] leading product developers. In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry's growth.

The opinions and insights presented in this study were also influenced by discussions held with senior stakeholders in the industry. The report features detailed transcripts of interviews held with the following industry and non-industry players:

  • Brigitte Angres (Co-founder, Cellendes)
  • Bill Anderson (President and CEO, Synthecon)
  • Anonymous (President and CEO, Anonymous)
  • Anonymous (Co-founder and Vice President, Anonymous)
  • Scott Brush (Vice President, BRTI Life Sciences)
  • Malcolm Wilkinson (Managing Director, Kirkstall)
  • Ryder Clifford (Director, QGel) and Simone Carlo Rizzi (Chief Scientific Officer, QGel)
  • Tanya Yankelevich (Director, Xylyx Bio)
  • Jens Kelm (Chief Scientific Officer, InSphero)
  • Walter Tinganelli (Group Leader, GSI)
  • Darlene Thieken (Project Manager, Nanofiber Solutions)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Questions Answered:

  • Who are the leading industry players engaged in the development of 3D cell culture products?
  • What are the most popular 3D cell culture products?
  • What are the different applications for which 3D cell culture products are currently being developed?
  • What are the key factors that are likely to influence the evolution of this market?
  • What is the trend of capital investments in the 3D cell culture systems market?
  • Which partnership models are commonly adopted by stakeholders in this industry?
  • How is the COVID-19 pandemic likely to impact the 3D cell culture systems market?
  • How is the current and future opportunity likely to be distributed across key market segments?
  • What are the anticipated future trends related to 3D cell culture systems market?

Chapter Outlines:

Chapter 2 is an executive summary of the key insights captured in our research. It offers a high-level view on the current state of 3D cell culture systems market and its likely evolution in the short to mid-term and long term.

Chapter 3 provides a general introduction to 3D culture systems, covering details related to the current and future trends in the domain. The chapter highlights the different types of cell cultures, the various methods of cell culturing and their application areas. The chapter also features a comparative analysis of 2D and 3D cultures, as well as highlights the current need and advantages of 3D culture systems.

Chapter 4 provides an overview of the classification of 3D culture systems, categorized as scaffold based systems (hydrogels / ECMs, solid scaffolds, micropatterned surfaces and microcarriers), scaffold free systems (attachment resistant surfaces, suspension systems and microfluidic systems) and 3D bioreactors. It also highlights, in detail, the underlying concepts, advantages and disadvantages of the aforementioned products.

Chapter 5 presents summaries of different techniques that are commonly used for fabrication of 3D matrices and scaffolds. It further provides information on the working principle, benefits and limitations associated with each method. In addition, the chapter features key takeaways from various research studies focused on matrices fabricated using the aforementioned methods.

Chapter 6 includes information on close to 160 industry players offering various 3D cell culture products. It features detailed analyses of these companies based on year of establishment, size of employee base, geographical presence, 3D cell culture format (scaffold based products, scaffold free products and 3D bioreactors), and type of product (hydrogels / ECMs, micropatterned surfaces, solid scaffolds, microcarriers, attachment resistant surfaces, suspension systems and microfluidic systems). In addition, the chapter provides information the companies that offer 3D culture related services and associated reagents / consumables. It also highlights the contemporary market trends in four schematic representations, which include [A] a heat map representation illustrating the distribution of developers based on type of 3D cell culture format and company size, [B] an insightful tree map representation of the developers, distributed on the basis of type of product and company size, and [C] a world map representation highlighting the regional distribution of developer companies.

Chapter 7 includes information on close to 150 scaffold based products that are either commercialized or under development. It features detailed analyses of these products based on status of development (under development, developed and not commercialized, and commercialized, type of product (hydrogels / ECMs, micropatterned surfaces, solid scaffolds, and microcarriers), source of 3D cultured cells (natural and synthetic), method used for fabrication (human based, animal based, plant based, and polymer based), and material used for fabrication. The chapter also highlights the contributions of various companies developing scaffold based products, presenting a detailed analysis based on their year of establishment, size of employee base and geographical presence.

Chapter 8 includes information on more than 60 scaffold free products that are either commercialized or under development. It features detailed analyses of these products based on status of development (under development, developed not commercialized, and commercialized, type of product (attachment resistant surfaces, suspension systems, and microfluidic systems), source of 3D cultured cells (natural and synthetic), method used for fabrication (human based, animal based, plant based, and polymer based), and material used for fabrication. The chapter also highlights the contributions of various companies developing scaffold free products, presenting a detailed analysis based on their year of establishment, size of employee base and geographical presence.

Chapter 9 includes information on more than 100 3D bioreactors that are either commercialized or under development. It features detailed analyses of these products based on the type of 3D bioreactor (single-use, perfusion, fed-batch, and fixed-bed), and typical working volume. The chapter also highlights the contributions of various companies developing 3D bioreactors, presenting a detailed analysis based on their year of establishment, size of employee base and geographical presence.

Chapter 10 presents a detailed overview and analysis on the most popular application areas, which include cancer research, drug discovery and toxicity screening, stem cell research, tissue engineering and regenerative medicine) for which various 3D cell culture products are being developed / used.

Chapter 11 features elaborate profiles of prominent players that are either engaged in the development or have developed popular scaffold based products (offering at least five hydrogel / ECM products). Each company profile features a brief overview of the company along with information on year of establishment, number of employees, location of headquarters and key members of the executive team, details of their respective product portfolio, recent developments and an informed future outlook.

Chapter 12 features elaborate profiles of prominent players that are either engaged in the development or have developed popular scaffold free products (offering at least three organ-on-chip products). Each company profile features a brief overview of the company along with information on year of establishment, number of employees, location of headquarters and key members of the executive team, details of their respective product portfolio, recent developments and an informed future outlook.

Chapter 13 features elaborate profiles of prominent players that are either engaged in the development or have developed 3D bioreactors (offering at least two bioreactors). Each company profile features a brief overview of the company along with information on year of establishment, number of employees, location of headquarters and key members of the executive team, details of their respective product portfolio, recent developments and an informed future outlook.

Chapter 14 features an analysis of the investments made in the period between 2015 and 2020, including seed financing, venture capital financing, debt financing, grants / awards, capital raised from IPOs and subsequent offerings, at various stages of development in small and mid-sized companies (established after 2005; with less than 200 employees) that are engaged in the development of 3D cell culture products, highlighting the growing interest of the venture capital community and other strategic investors, in this domain.

Chapter 15 features in-depth analysis and discussion of the various partnerships inked between the players in this market, during the period, 2015 and 2020 (till September), based on several parameters, such as year of agreement, type of partnership (product development / commercialization agreements, product integration / utilization agreements, product licensing agreement, research and development agreements, distribution agreements, acquisitions, joint venture and other agreements), 3D cell culture format (scaffold based products, scaffold free products and 3D bioreactor), type of product (hydrogels / ECMs, micropatterned surfaces, solid scaffolds, microcarriers, attachment resistant surfaces, suspension systems and microfluidic systems), and most active players. It also provides the regional distribution of players involved in the collaborations.

Chapter 16 provides an in-depth patent analysis presenting an overview of how the industry is evolving from the R&D perspective. For this analysis, we considered over 8,400 patents that have been filed / granted for 3D cell culture products, since 2015, highlighting key trends associated with these patents, across type of patents, publication year, geographical location, type of applicants, issuing authorities involved, CPC symbols, emerging focus areas, leading players (in terms of number of patents granted / filed in the given time period), patent characteristics and geography. It also includes a detailed patent valuation analysis.

Chapter 17 presents an insightful market forecast analysis, highlighting the likely growth of 3D cell culture systems market, for the time period 2020-2030. In order to provide an informed future outlook, our projections have been segmented on the basis of [A] 3D cell culture scaffold (scaffold based systems, scaffold free systems, and 3D bioreactors), [B] type of product (hydrogels / ECMs, micropatterned surfaces, solid scaffolds, microcarriers, attachment resistant surfaces, suspension systems, and microfluidic systems), [C] area of application (cancer research, drug discovery / toxicity testing, stem cell research, and regenerative medicine / tissue engineering), [D] purpose (research use and therapeutic use), [E] key geographical regions (North America, Europe, Asia-Pacific, Latin America, MENA (Middle East and North Africa) and RoW (Rest of the World)), and [F] leading product developers.

Chapter 18 presents insights from the survey conducted for this study. We invited over 150 stakeholders involved in the development of 3D cell culture systems. The participants, who were primarily Founder / CXO / Senior Management level representatives of their respective companies, helped us develop a deeper understanding on the nature of their products / services and the associated commercial potential.

Chapter 19 summarizes the overall report, wherein we have mentioned all the key facts and figures described in the previous chapters. The chapter also highlights important evolutionary trends that were identified during the course of the study and are expected to influence the future of the 3D cell culture systems market.

Chapter 20 is a collection of transcripts of interviews conducted with various stakeholders in the industry. The chapter provides a brief overview of the companies and details of interviews held with Brigitte Angres (Co-founder, Cellendes), Bill Anderson (President and CEO, Synthecon), anonymous (President and CEO, Anonymous), anonymous (Co-founder and Vice President, Anonymous), Scott Brush (Vice President, BRTI Life Sciences), Malcolm Wilkinson (Managing Director, Kirkstall), Ryder Clifford (Director, QGel) and Simone Carlo Rizzi (Chief Scientific Officer, QGel), Tanya Yankelevich (Director, Xylyx Bio), Jens Kelm (Chief Scientific Officer, InSphero), Walter Tinganelli (Group Leader, GSI), and Darlene Thieken (Project Manager, Nanofiber Solutions)

Chapter 21 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

Chapter 22 is an appendix, which contains the list of companies and organizations mentioned in the report.

Table of Contents

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
  • 1.3. Key Questions Answered
  • 1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1. Chapter Overview
  • 3.2. Types of Cell Cultures
    • 3.2.1. Primary Cell Cultures
    • 3.2.2. Cell Lines
  • 3.3. Morphology of Cells in Culture
  • 3.4. Transition from 2D to 3D Cell Cultures
  • 3.5. Overview of 3D Cell Culturing
    • 3.5.1. Components of the Extracellular Matrix (ECM)
    • 3.5.2. In Vitro Cell Culturing
    • 3.5.3. Selection of Culture Format
  • 3.6. Establishment and Maintenance of Cell Cultures
    • 3.6.1. Isolating Cells from Tissues
    • 3.6.2. Maintaining Cells in Culture
    • 3.6.3. Sub-Culturing / Passaging
    • 3.6.4. Cryogenic Storage
  • 3.7. Requirements for Maintaining the Health of Cell Cultures
    • 3.7.1. Safety Guidelines in a Cell Culture Facility
    • 3.7.2. Cell Culture Health and Optimal Conditions for Growth
    • 3.7.3. Concerns Related to Cross Contamination
    • 3.7.4. Methods to Prevent Contamination
  • 3.8. Need for 3D Cell Culture Systems
    • 3.8.1. Model Systems
    • 3.8.2. Drug Discovery and Preclinical Research
    • 3.8.3. Cancer Research
    • 3.8.4. Virology Research
    • 3.8.5. Genetic Engineering and Gene Therapy Research
  • 3.9. Advantages and Limitations of 3D Cell Culture Systems
  • 3.10. Future Perspectives

4. CLASSIFICATION OF 3D CELL CULTURE SYSTEMS

  • 4.1. 3D Cell Culture Classification
  • 4.2. Scaffold based 3D Cell Cultures
    • 4.2.1. Hydrogels / ECM Analogs
    • 4.2.2. Solid Scaffolds
    • 4.2.3. Micropatterned Surfaces
    • 4.2.4. Microcarriers
  • 4.3. Scaffold Free 3D Cell Cultures
    • 4.3.1. Attachment Resistant Surfaces
    • 4.3.2. Suspension Culture Systems
      • 4.3.2.1. Hanging Drop Plates
      • 4.3.2.2. Magnetic Levitation and 3D Bioprinting
    • 4.3.3. Microfluidic Surfaces and Organs-on-Chips
    • 4.3.4. 3D Bioreactors
  • 4.4. Organoids

5. FABRICATION OF 3D MATRICES AND SCAFFOLDS

  • 5.1. Chapter Overview
  • 5.2. Methods for Fabricating Porous Scaffolds
    • 5.2.1. Particulate Leaching
    • 5.2.2. Solvent Casting
    • 5.2.3. Emulsion Templating
    • 5.2.4. Gas Foaming
    • 5.2.5. Melt Molding
    • 5.2.6. Microsphere Sintering
  • 5.3. Methods for Fabricating Fibrous Scaffolds
    • 5.3.1. Electrospinning
    • 5.3.2. Phase Separation
    • 5.3.3. Self-Assembly
    • 5.3.4. Fiber Mesh and Fiber Bonding
  • 5.4. Methods for Fabricating Hydrogels
    • 5.4.1. Gelation
    • 5.4.2. Solvent Casting and Particulate Leaching
    • 5.4.3. Gas Foaming
    • 5.4.4. Freeze Drying
    • 5.4.5. Co-polymerization / Crosslinking Methods
    • 5.4.6. Microfluidics
  • 5.5. Methods for Fabricating Custom Scaffolds
    • 5.5.1. Stereo-Lithography
    • 5.5.2. 3D Bioprinting and Selective Laser Sintering (SLS)
    • 5.5.3. Fused Deposition Modeling
    • 5.5.4. Membrane Lamination
    • 5.5.5. Rapid Prototyping / Solid Free-Form Technique
  • 5.6. Methods for Fabricating Microspheres
    • 5.6.1. Solvent Evaporation
    • 5.6.2. Single and Double Emulsification
    • 5.6.3. Particle Aggregation
  • 5.7. Methods for Fabricating Native Scaffolds
    • 5.7.1. Decellularization

6. 3D CELL CULTURE SYSTEMS: DEVELOPER LANDSCAPE

  • 6.1. Chapter Overview
  • 6.2. 3D Cell Culture System Developers: Overall Market Landscape
    • 6.2.1. Analysis by Year of Establishment
    • 6.2.2. Analysis by Company Size
    • 6.2.3. Analysis by Location of Headquarters
    • 6.2.4. Analysis by 3D Cell Culture Format
    • 6.2.5. Analysis by Type of Product
  • 6.3. Heat Map Representation: Analysis by 3D Cell Culture Format and Location of Headquarters
  • 6.4. Tree Map Representation: Analysis by Company Size and Type of Product
  • 6.5. World Map Representation: Analysis by Location of Regional Headquarters
  • 6.6. 3D Cell Cultures: List of Service Providers
  • 6.7. 3D Cell Cultures: List of Assays, Kits and Reagents

7. MARKET LANDSCAPE: SCAFFOLD BASED PRODUCTS

  • 7.1. Chapter Overview
  • 7.2. Scaffold based Products: Overall Market Landscape
    • 7.2.1. Analysis by Status of Development
    • 7.2.2. Analysis by Type of Product
    • 7.2.3. Analysis by Source of 3D Cultured Cells
    • 7.2.4. Analysis by Method Used for Fabrication
    • 7.2.5. Analysis by Material Used for Fabrication
    • 7.2.6. Analysis by Type of Product and Source of 3D Cultured Cells
    • 7.2.7. Analysis by Type of Product and Method Used for Fabrication
  • 7.3. Scaffold Based Products: Developer Landscape
    • 7.3.1. Analysis by Year of Establishment
    • 7.3.2. Analysis by Company Size
    • 7.3.3. Analysis by Location of Headquarters
  • 7.4. Leading Developers: Analysis by Number of Scaffold based Products
  • 7.5. Tree Map Representation: Analysis by Type of Product and Company Size

8. MARKET LANDSCAPE: SCAFFOLD FREE PRODUCTS

  • 8.1. Chapter Overview
  • 8.2. Scaffold Free Products: Overall Market Landscape
    • 8.2.1. Analysis by Status of Development
    • 8.2.2. Analysis by Type of Product
    • 8.2.3. Analysis by Source of 3D Cultured Cells
    • 8.2.4. Analysis by Method Used for Fabrication
    • 8.2.5. Analysis by Material Used for Fabrication
    • 8.2.6. Analysis by Type of Product and Source of 3D Cultured Cells
    • 8.2.7. Analysis by Type of Product and Method Used for Fabrication
  • 8.3. Scaffold Free Products: Developer Landscape
    • 8.3.1. Analysis by Year of Establishment
    • 8.3.2. Analysis by Company Size
    • 8.3.3. Analysis by Location of Headquarters
  • 8.4. Leading Developers: Analysis by Number of Scaffold Free Products
  • 8.5. Tree Map Representation: Analysis by Type of Product and Company Size

9. MARKET LANDSCAPE: 3D BIOREACTORS

  • 9.1. Chapter Overview
  • 9.2. 3D Bioreactors: Overall Market Landscape
    • 9.2.1. Analysis by Type of 3D Bioreactor
    • 9.2.2. Analysis by Working Volume
  • 9.3. 3D Bioreactors: Developer Landscape
    • 9.3.1. Analysis by Year of Establishment
    • 9.3.2. Analysis by Company Size
    • 9.3.3. Analysis by Location of Headquarters
  • 9.4. Leading Developers: Analysis by Number of 3D Bioreactors

10. KEY APPLICATION AREAS

  • 10.1. Chapter Overview
  • 10.2. 3D Cell Culture Systems in Cancer Research
    • 10.2.1. Need for 3D Culture Systems in Cancer Research
      • 10.2.1.1. Improving Cancer Drug Screening with 3D Culture Systems
  • 10.3. 3D Cell Culture Systems in Drug Discovery and Toxicity Screening
    • 10.3.1. Drug Development Studies
    • 10.3.2. Toxicity Screening
      • 10.3.2.1. 3D Liver Models
      • 10.3.2.2. Other 3D Models
  • 10.4. 3D Cell Culture Systems in Stem Cell Research
    • 10.4.1. Potential of 3D Culture Systems in Stem Cell Differentiation
    • 10.4.2. In Vitro 3D Microenvironment to Induce Embryoid Body Formation
  • 10.5. 3D Cell Cultures in Regenerative Medicine and Tissue Engineering
  • 10.6. 3D Cell Culture Systems: Analysis by Key Application Areas
    • 10.6.1. 3D Cell Culture Systems: Analysis by Key Application Areas and 3D Cell Culture Format
      • 10.6.1.1. Scaffold based 3D Products: Analysis by Key Application Areas
      • 10.6.1.2. Scaffold Free 3D Products: Analysis by Key Application Areas
      • 10.6.1.3. 3D Bioreactors: Analysis by Key Application Areas

11. COMPANY PROFILES: SCAFFOLD BASED PRODUCTS (HYDROGEL / ECM DEVELOPERS)

  • 11.1. Chapter Overview
    • 11.1.1. 3D Biotek
      • 11.1.1.1. Company Overview
      • 11.1.1.2. Product Portfolio
      • 11.1.1.3. Recent Developments and Future Outlook
    • 11.1.2. Advanced BioMatrix
      • 11.1.2.1. Company Overview
      • 11.1.2.2. Product Portfolio
      • 11.1.2.3. Recent Development and Future Outlook
    • 11.1.3. Alphabioregen
      • 11.1.3.1. Company Overview
      • 11.1.3.2. Product Portfolio
      • 11.1.3.3. Recent Developments and Future Outlook
    • 11.1.4. Corning Life Sciences
      • 11.1.4.1. Company Overview
      • 11.1.4.2. Product Portfolio
      • 11.1.4.3. Recent Developments and Future Outlook
    • 11.1.5. REPROCELL
      • 11.1.5.1. Company Overview
      • 11.1.5.2. Product Portfolio
      • 11.1.5.3. Recent Developments and Future Outlook

12. COMPANY PROFILES: SCAFFOLD FREE PRODUCTS (ORGAN-ON-CHIP DEVELOPERS)

  • 12.1. Chapter Overview
    • 12.1.1. CN Bio Innovations
      • 12.1.1.1. Company Overview
      • 12.1.1.2. Financial Information
      • 12.1.1.3. Product Portfolio
      • 12.1.1.4. Recent Developments and Future Outlook
    • 12.1.2. Emulate
      • 12.1.2.1. Company Overview
      • 12.1.2.2. Financial Information
      • 12.1.2.3. Product Portfolio
      • 12.1.2.4. Recent Developments and Future Outlook
    • 12.1.3. InSphero
      • 12.1.3.1. Company Overview
      • 12.1.3.2. Financial Information
      • 12.1.3.3. Product Portfolio
      • 12.1.3.4. Recent Developments and Future Outlook
    • 12.1.4. Mimetas
      • 12.1.4.1. Company Overview
      • 12.1.4.2. Financial Information
      • 12.1.4.3. Product Portfolio
      • 12.1.4.4. Recent Developments and Future Outlook
    • 12.1.5. TissUse
      • 12.1.5.1. Company Overview
      • 12.1.5.2. Product Portfolio
      • 12.1.5.3. Recent Developments and Future Outlook

13. COMPANY PROFILES: 3D BIOREACTORS

  • 13.1. Chapter Overview
  • 13.2. BISS TGT
    • 13.2.1. Company Overview
    • 13.2.2. Product Portfolio
    • 13.2.3. Recent Developments and Future Outlook
  • 13.3. Celartia
    • 13.3.1. Company Overview
    • 13.3.2. Product Portfolio
    • 13.3.3. Recent Developments and Future Outlook
  • 13.4. Cell Culture
    • 13.4.1. Company Overview
    • 13.4.2. Product Portfolio
    • 13.4.3. Recent Developments and Future Outlook
  • 13.5. Cesco Bioengineering
    • 13.5.1. Company Overview
    • 13.5.2. Product Portfolio
    • 13.5.3. Recent Developments and Future Outlook
  • 13.6. Flexcell International
    • 13.6.1. Company Overview
    • 13.6.2. Product Portfolio
    • 13.6.3. Recent Developments and Future Outlook
  • 13.7. PBS Biotech
    • 13.7.1. Company Overview
    • 13.7.2. Product Portfolio
    • 13.7.3. Recent Developments and Future Outlook
  • 13.8. Synthecon
    • 13.8.1. Company Overview
    • 13.8.2. Product Portfolio
    • 13.8.3. Recent Developments and Future Outlook

14. FUNDING AND INVESTMENT ANALYSIS

  • 14.1. Chapter Overview
  • 14.2. Types of Funding
  • 14.3. 3D Cell Culture Systems: Funding and Investment Analysis
    • 14.3.1. Analysis by Number of Funding Instances
    • 14.3.2. Analysis by Amount Invested
    • 14.3.3. Analysis by Type of Funding
    • 14.3.4. Analysis by 3D Cell Culture Format
    • 14.3.5. Analysis by Type of Product
    • 14.3.6. Analysis by Geography
    • 14.3.7. Most Active Players: Analysis by Number of Funding Instances
    • 14.3.8. Most Active Players: Analysis by Amount of Funding
    • 14.3.9. Most Active Investors: Analysis by Number of Instances
  • 14.4 Concluding Remarks

15. PARTNERSHIPS AND COLLABORATIONS

  • 15.1. Chapter Overview
  • 15.2. Partnership Models
  • 15.3. 3D Cell Culture Systems: Recent Partnerships and Collaborations
    • 15.3.1. Analysis by Year of Partnership
    • 15.3.2. Analysis by Type of Partnership
      • 15.3.2.1. Analysis by Year of Partnership and Type of Partnership
      • 15.3.2.2. Analysis by Company Size and Type of Partnership
    • 15.3.3. Analysis by Type of Partner
      • 15.3.3.1. Analysis by Year of Partnership and Type of Partner
      • 15.3.3.2. Analysis by Type of Partnership and Type of Partner
    • 15.3.4. Analysis by 3D Cell Culture Format
      • 15.3.4.1. Analysis by Year of Partnership and 3D Cell Culture Format
      • 15.3.4.2. Analysis by Type of Partnership and 3D Cell Culture Format
    • 15.3.5. Analysis by Type of Product
      • 15.3.5.1. Analysis by Year of Partnership and Type of Product
      • 15.3.5.2. Analysis by Type of Partnership and Type of Product
    • 15.3.6. Most Active Players: Analysis by Number of Partnerships
    • 15.3.7. Regional Analysis
    • 15.3.8. Intercontinental and Intracontinental Agreements

16. PATENT ANALYSIS

  • 16.1. Chapter Overview
  • 16.2. Scope and Methodology
  • 16.3. 3D Cell Culture Systems: Patent Analysis
    • 16.3.1. Analysis by Type of Patent
    • 16.3.2. Analysis by Publication Year
    • 16.3.3. Analysis by Issuing Authority
    • 16.3.4. Analysis by CPC Symbols
    • 16.3.5. Emerging Focus Area
    • 16.3.6. Leading Players: Analysis by Number of Patents
  • 16.4. 3D Cell Culture Systems: Patent Valuation Analysis
  • 16.5. Leading Patents: Analysis by Number of Citations

17. MARKET FORECAST

  • 17.1. Chapter Overview
  • 17.2. Forecast Methodology and Key Assumptions
  • 17.3. Impact of COVID-19 Pandemic on Global 3D Cell Culture Market
  • 17.4. Global 3D Cell Culture Market, 2020-2030
  • 17.5. Global 3D Cell Culture Market: Distribution by Business Segment
    • 17.5.1. 3D Cell Culture Systems Market, 2020-2030
    • 17.5.2. 3D Cell Culture Consumables Market, 2020-2030
    • 17.5.3. 3D Cell Culture Services Market, 2020-2030
  • 17.6. Global 3D Cell Culture Systems Market: Distribution by 3D Cell Culture Format
    • 17.6.1. 3D Cell Culture Systems Market for Scaffold based Products, 2020-2030
    • 17.6.2. 3D Cell Culture Systems Market for Scaffold Free Products, 2020-2030
    • 17.6.3. 3D Cell Culture Systems Market for 3D Bioreactors, 2020-2030
  • 17.7. Global 3D Cell Culture Systems Market: Distribution by Type of Product
    • 17.7.1. 3D Cell Culture Systems Market for Attachment Resistant Surfaces, 2020-2030
    • 17.7.2. 3D Cell Culture Systems Market for Hydrogels / ECMs, 2020-2030
    • 17.7.3 3D Cell Culture Systems Market for Micropatterned Surface, 2020-2030
    • 17.7.4. 3D Cell Culture Systems Market for Microcarriers, 2020-2030
    • 17.7.5. 3D Cell Culture Systems Market for Microfluidic Systems, 2020-2030
    • 17.7.6. 3D Cell Culture Systems Market for Solid Scaffolds, 2020-2030
    • 17.7.7. 3D Cell Culture Systems Market for Suspension Culture Systems, 2020-2030
  • 17.8. Global 3D Cell Culture Systems Market: Distribution by Area of Application
    • 17.8.1. 3D Cell Culture Systems Market for Cancer Research, 2020-2030
    • 17.8.2 3D Cell Culture Systems Market for Drug Discovery and Toxicity Testing, 2020-2030
    • 17.8.3. 3D Cell Culture Systems Market for Stem Cell Research, 2020-2030
    • 17.8.4. 3D Cell Culture Systems Market for Regenerative Medicine and Tissue Engineering, 2020-2030
  • 17.9. Global 3D Cell Culture Systems Market: Distribution by Purpose
    • 17.9.1. 3D Cell Culture Systems Market for Research Use, 2020-2030
    • 17.9.2 3D Cell Culture Systems Market for Therapeutic Use, 2020-2030
  • 17.10. Global 3D Cell Culture Systems Market: Distribution by Geography
    • 17.10.1. 3D Cell Culture Systems Market in North America, 2020-2030
    • 17.10.2 3D Cell Culture Systems Market in Europe, 2020-2030
    • 17.10.3. 3D Cell Culture Systems Market in Asia-Pacific, 2020-2030
    • 17.10.4. 3D Cell Culture Systems Market in Latin America, 2020-2030
    • 17.10.4. 3D Cell Culture Systems Market in Middle East and North Africa (MENA), 2020-2030
    • 17.10.5. 3D Cell Culture Systems Market in Rest of the World, 2020-2030
  • 17.11. Global 3D Cell Culture Systems Market: Distribution by Leading Players, 2020
  • 17.12. Concluding Remarks

18. SURVEY ANALYSIS

  • 18.1. Chapter Overview
  • 18.2. Overview of Respondents
    • 18.2.1. Designation of Respondents
  • 18.3. Survey Insights
    • 18.3.1. 3D Cell Culture Format
    • 18.3.2. Type of Product(s) Offered
    • 18.3.3. Status of Development of Product(s)
    • 18.3.4. Source of 3D Cultured Cells
    • 18.3.5. Method Used for Fabrication
    • 18.3.6. Area(s) of Application
    • 18.3.7. Services Offered for 3D Cell Cultures
    • 18.3.8. Current and Future Market Opportunity

19. CONCLUSION

20. EXECUTIVE INSIGHTS

  • 20.1. Chapter Overview
  • 20.2. Cellendes
    • 20.2.1. Company Snapshot
    • 20.2.2. Interview Transcript: Brigitte Angres, Co-founder
  • 20.3. Synthecon
    • 20.3.1. Company Snapshot
    • 20.3.2. Interview Transcript: Bill Anderson, President and CEO
  • 20.4. Anonymous
    • 20.4.1. Interview Transcript: Anonymous, President and CEO
  • 20.5. Anonymous
    • 20.5.1. Interview Transcript: Anonymous, Co-founder and Vice President
  • 20.6. BRTI Life Sciences
    • 20.6.1. Company Snapshot
    • 20.6.2. Interview Transcript: Scott Brush, Vice President
  • 20.7. Kirkstall
    • 20.7.1. Company Snapshot
    • 20.7.2. Interview Transcript: Malcolm Wilkinson, Managing Director
  • 20.8. QGel
    • 20.8.1. Company Snapshot
    • 20.8.2. Interview Transcript: Ryder Clifford, Director and Simone Carlo Rizzi, Chief Scientific Officer
  • 20.9. Xylyx Bio
    • 20.9.1. Company Snapshot
    • 20.9.2. Interview Transcript: Tanya Yankelevich, Director
  • 20.10. InSphero
    • 20.10.1. Company Snapshot
    • 20.10.2. Interview Transcript: Jens Kelm, Chief Scientific Officer
  • 20.11. GSI
    • 20.11.1. Company Snapshot
    • 20.11.2. Interview Transcript: Walter Tinganelli, Group Leader
  • 20.12. Nanofiber Solutions
    • 20.12.1. Company Snapshot
    • 20.12.2. Interview Transcript: Darlene Thieken, Project Manager

21. APPENDIX I: TABULATED DATA

22. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

  • Figure 3.1: Classification of Cell Cultures
  • Figure 3.2: Types of 2D and 3D Cell Culture Systems
  • Figure 3.3: Key Components of ECM
  • Figure 3.4: Factors Influencing the Selection of 3D Cell Culture Systems
  • Figure 3.5: Methods Used for Isolation of Cells from Tissues
  • Figure 3.6: Methods Used for Cryogenic Storage
  • Figure 3.7: Required Biosafety Levels for Cell Cultures
  • Figure 3.8: Key Applications of Cell Cultures
  • Figure 3.9: Shapes of 3D Spheroids Generated via 3D Cell Culture Systems
  • Figure 3.10: Advantages and Limitations of 3D Cell Culture Systems
  • Figure 4.1: Classification of 3D Cell Culture Systems
  • Figure 4.2: Natural Components of ECM Used for Fabrication of Scaffolds
  • Figure 4.3: Advantages and Disadvantages of Hydrogels
  • Figure 4.4: Advantages of Microcarriers
  • Figure 4.5: Techniques Used for Formation of 3D Spheroids
  • Figure 4.6: Structures of Spinner Flask and Rotating Wall Bioreactors
  • Figure 6.1: 3D Cell Culture System Developers: Distribution by Year of Establishment
  • Figure 6.2: 3D Cell Culture System Developers: Distribution by Company Size
  • Figure 6.3: 3D Cell Culture System Developers: Distribution by Location of Headquarters
  • Figure 6.4: 3D Cell Culture System Developers: Distribution by 3D Cell Culture Format
  • Figure 6.5: 3D Cell Culture System Developers: Distribution by Type of Product
  • Figure 6.6: 3D Cell Culture System Developers: Distribution by Number of 3D Cell Culture Products
  • Figure 6.7: Heat Map Representation: Distribution by 3D Cell Culture Format and Location of Headquarters
  • Figure 6.8: Tree Map Representation: Distribution by Company Size and Type of Product
  • Figure 6.9: World Map Representation: Distribution by Location of Regional Headquarters
  • Figure 7.1: Scaffold Based Products: Distribution by Status of Development
  • Figure 7.2: Scaffold Based Products: Distribution by Type of Product
  • Figure 7.3: Scaffold Based Products: Distribution by Source of 3D Cultured Cells
  • Figure 7.4: Scaffold Based Products: Distribution by Method Used for Fabrication
  • Figure 7.5: Scaffold Based Products: Distribution by Material Used for Fabrication
  • Figure 7.6: Scaffold Based Products: Distribution by Type of Product and Source of 3D Cultured Cells
  • Figure 7.7: Scaffold Based Products: Distribution by Type of Product and Method Used for Fabrication
  • Figure 7.8: Scaffold Based Product Developers: Distribution by Year of Establishment
  • Figure 7.9: Scaffold Based Product Developers: Distribution by Company Size
  • Figure 7.10: Scaffold Based Product Developers: Distribution by Location of Headquarters
  • Figure 7.11: Leading Developers: Distribution by Number of Scaffold Based Products
  • Figure 7.12: Tree Map Representation: Distribution by Type of Product and Company Size
  • Figure 8.1: Scaffold Free Products: Distribution by Status of Development
  • Figure 8.2: Scaffold Free Products: Distribution by Type of Product
  • Figure 8.3: Scaffold Free Products: Distribution by Source of 3D Cultured Cells
  • Figure 8.4: Scaffold Free Products: Distribution by Method Used for Fabrication
  • Figure 8.5: Scaffold Free Products: Distribution by Material Used for Fabrication
  • Figure 8.6: Scaffold Free Products: Distribution by Type of Product and Source of 3D Cultured Cells
  • Figure 8.7: Scaffold Free Products: Distribution by Type of Product and Method Used for Fabrication
  • Figure 8.8: Scaffold Free Product Developers: Distribution by Year of Establishment
  • Figure 8.9: Scaffold Free Product Developers: Distribution by Company Size
  • Figure 8.10: Scaffold Free Product Developers: Distribution by Location of Headquarters
  • Figure 8.11: Leading Developers: Distribution by Number of Scaffold Free Products
  • Figure 8.12: Tree Map Representation: Distribution by Type of Product and Company Size
  • Figure 9.1: 3D Bioreactors: Distribution by Type of 3D Bioreactor
  • Figure 9.2: 3D Bioreactors: Distribution by Working Volume
  • Figure 9.3: 3D Bioreactor Developers: Distribution by Year of Establishment
  • Figure 9.4: 3D Bioreactor Developers: Distribution by Company Size
  • Figure 9.5: 3D Bioreactor Developers: Distribution by Location of Headquarters
  • Figure 9.6: Leading Developers: Distribution by Number of 3D Bioreactors
  • Figure 10.1: Key Application Areas of 3D Cell Culture Systems
  • Figure 10.2: 3D Cell Culture Systems in Cancer Research
  • Figure 10.3: 3D Cell Culture Systems in Drug Discovery and Toxicity Screening
  • Figure 10.4: Methods Used for Embryoid Body Formation
  • Figure 10.5: Top-Down and Bottom-Up Approaches for Tissue Engineering
  • Figure 10.6: 3D Cell Culture Systems: Distribution by Key Application Areas
  • Figure 10.7: 3D Cell Culture Systems: Distribution by Key Application Areas and 3D Cell Culture Format
  • Figure 10.8: Scaffold Based 3D Products: Distribution by Key Application Areas
  • Figure 10.9: Scaffold Free 3D Products: Distribution by Key Application Areas
  • Figure 10.10: 3D Bioreactors: Distribution by Key Application Areas
  • Figure 13.1: Key Features of 3D Perfusion Bioreactors
  • Figure 13.2: MagDrive and AirDrive Mechanisms for PBS Bioreactors
  • Figure 13.3: Advantages of Rotary Cell Culture System (RCCS)
  • Figure 14.1: Funding and Investments: Distribution of Recipient Companies by Year of Establishment and Type of Funding, 2015-Q3 2020
  • Figure 14.2: Funding and Investments: Cumulative Number of Funding Instances by Year, 2015 - Q3 2020
  • Figure 14.3: Funding and Investments: Cumulative Amount Invested, 2015 - Q3 2020 (USD Million)
  • Figure 14.4: Funding and Investments: Distribution of Instances by Type of Funding, 2015 - Q3 2020
  • Figure 14.5: Funding and Investments: Year-Wise Distribution of Instances and Type of Funding, 2015 - Q3 2020
  • Figure 14.6: Funding and Investments: Distribution by Amount Invested and Type of Funding, 2015 - Q3 2020 (USD Million)
  • Figure 14.7: Funding and Investments: Year-Wise Distribution of Amount Invested and Type of Funding, 2015 - Q3 2020
  • Figure 14.8: Funding and Investments: Distribution by Number of Instances and Amount Invested by 3D Cell Culture Format, 2015 - Q3 2020
  • Figure 14.9: Funding and Investments: Distribution by Number of Instances and Amount Invested by Type of Product, 2015 - Q3 2020
  • Figure 14.10: Funding and Investments: Distribution by Geography
  • Figure 14.11: Funding and Investments: Regional Distribution by Total Amount Invested, 2015 - Q3 2020
  • Figure 14.12: Most Active Players: Distribution by Number of Funding Instances, 2015 - Q3 2020
  • Figure 14.13: Most Active Players: Distribution by Amount Raised, 2015 - Q3 2020 (USD Million)
  • Figure 14.14: Most Active Investors: Distribution by Number of Funding Instances, 2015-Q3 2020
  • Figure 14.15: Funding and Investment Summary, 2015 - Q3 2020 (USD Million)
  • Figure 15.1: Partnerships and Collaborations: Cumulative Year-Wise Trend, 2015 - Q3 2020
  • Figure 15.2: Partnerships and Collaborations: Distribution by Type of Partnership
  • Figure 15.3: Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partnership
  • Figure 15.4: Partnerships and Collaborations: Distribution by Company Size and Type of Partnership
  • Figure 15.5: Partnerships and Collaborations: Distribution by Type of Partner
  • Figure 15.6: Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner
  • Figure 15.7: Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
  • Figure 15.8: Partnerships and Collaborations: Distribution by 3D Cell Culture Format
  • Figure 15.9: Partnerships and Collaborations: Distribution by Year of Partnership and 3D Cell Culture Format
  • Figure 15.10: Partnerships and Collaborations: Distribution by Type of Partnership and 3D Cell Culture Format
  • Figure 15.11: Partnerships and Collaborations: Distribution by Type of Product
  • Figure 15.12: Partnerships and Collaborations: Distribution by Year of Partnership and Type of Product
  • Figure 15.13: Partnerships and Collaborations: Distribution by Type of Partnership and Type of Product
  • Figure 15.14: Most Active Players: Distribution by Number of Partnerships
  • Figure 15.15: Partnerships and Collaborations: Regional Distribution
  • Figure 15.16: Partnerships and Collaborations: Distribution by Intercontinental and Intracontinental Agreements
  • Figure 16.1: Patent Analysis: Distribution by Type of Patent
  • Figure 16.2: Patent Analysis: Cumulative Distribution by Publication Year, 2015 - Q3 2020
  • Figure 16.3: Patent Analysis: Distribution of Granted Patents by Publication Year, 2015 - Q3 2020
  • Figure 16.4: Patent Analysis: Distribution of Filed Patents Publication Year, 2015 - Q3 2020
  • Figure 16.5: Patent Analysis: Distribution by Patent Type and Publication Year, 2015 - Q3 2020
  • Figure 16.6: Patent Analysis: Distribution by Issuing Authority
  • Figure 16.7: Patent Analysis: Distribution by CPC Symbols
  • Figure 16.8: Patent Analysis: Distribution by Emerging Focus Area
  • Figure 16.9: Patent Analysis: Cumulative Year-wise Distribution by Type of Applicant, 2015 - Q3 2020
  • Figure 16.10: Leading Patent Assignees (Industry Players): Distribution by Number of Patents
  • Figure 16.11: Leading Patent Assignees (Non-Industry Players): Distribution by Number of Patents
  • Figure 16.12: Patent Analysis: Distribution by Patent Age, 2000-2020
  • Figure 16.13: Patent Analysis: Distribution by Proprietary Scoring Criteria
  • Figure 16.14: Patent Analysis: Valuation Analysis
  • Figure 17.1: Global 3D Cell Culture Market, 2020-2030 (USD Million)
  • Figure 17.2: Global 3D Cell Culture Market: Distribution by Business Segment, 2020 and 2030
  • Figure 17.3: 3D Cell Culture Systems Market, 2020-2030 (USD Million)
  • Figure 17.4: 3D Cell Culture Consumables Market, 2020-2030 (USD Million)
  • Figure 17.5: 3D Cell Culture Services Market, 2020-2030 (USD Million)
  • Figure 17.6: Global 3D Cell Culture Systems Market: Distribution by 3D Cell Culture Format, 2020-2030
  • Figure 17.7: 3D Cell Culture Systems Market for Scaffold Based Products, 2020-2030 (USD Million)
  • Figure 17.8: 3D Cell Culture Systems Market for Scaffold Free Products, 2020-2030 (USD Million)
  • Figure 17.9: 3D Cell Culture Systems Market for 3D Bioreactors, 2020-2030 (USD Million)
  • Figure 17.10: Global 3D Cell Culture Systems Market: Distribution by Type of Product, 2020 and 2030
  • Figure 17.11: 3D Cell Culture Systems Market for Attachment Resistant Surfaces, 2020-2030 (USD Million)
  • Figure 17.12: 3D Cell Culture Systems Market for Hydrogels / ECMs, 2020-2030 (USD Million)
  • Figure 17.13: 3D Cell Culture Systems Market for Micropatterned Surface, 2020-2030 (USD Million)
  • Figure 17.14: 3D Cell Culture Systems Market for Microcarriers, 2020-2030 (USD Million)
  • Figure 17.15: 3D Cell Culture Systems Market for Microfluidic Systems, 2020-2030 (USD Million)
  • Figure 17.16: 3D Cell Culture Systems Market for Solid Scaffolds, 2020-2030 (USD Million)
  • Figure 17.17: 3D Cell Culture Systems Market for Suspension Cultures, 2020-2030 (USD Million)
  • Figure 17.18: Global 3D Cell Culture Systems Market: Distribution by Area of Application, 2020 and 2030
  • Figure 17.19: 3D Cell Culture Systems Market for Cancer Research, 2020-2030 (USD Million)
  • Figure 17.20: 3D Cell Culture Systems Market for Drug Discovery and Toxicity Testing, 2020-2030 (USD Million)
  • Figure 17.21: 3D Cell Culture Systems Market for Stem Cell Research, 2020-2030 (USD Million)
  • Figure 17.22: 3D Cell Culture Systems Market for Regenerative Medicine and Tissue Engineering, 2020-2030 (USD Million)
  • Figure 17.23: Global 3D Cell Culture Systems Market: Distribution by Purpose, 2020-2030
  • Figure 17.24: 3D Cell Culture Systems Market for Research Use, 2020-2030 (USD Million)
  • Figure 17.25: 3D Cell Culture Systems Market for Therapeutic Use, 2020-2030 (USD Million)
  • Figure 17.26: Global 3D Cell Culture Systems Market: Distribution by Geography, 2020- 2030
  • Figure 17.27: 3D Cell Culture Systems Market in North America, 2020-2030 (USD Million)
  • Figure 17.28: 3D Cell Culture Systems Market in Europe, 2020-2030 (USD Million)
  • Figure 17.29: 3D Cell Culture Systems Market in Asia-Pacific, 2020-2030 (USD Million)
  • Figure 17.30: 3D Cell Culture Systems Market in Latin America, 2020-2030 (USD Million)
  • Figure 17.31: 3D Cell Culture Systems Market in Middle East and North Africa (MENA), 2020-2030 (USD Million)
  • Figure 17.32: 3D Cell Culture Systems Market in Rest of the World, 2020-2030 (USD Million)
  • Figure 17.33: Global 3D Cell Culture Systems Market: Distribution by Leading Players, 2020
  • Figure 17.34: Global 3D Cell Culture Systems Market: Conservative, Base and Optimistic Scenarios, 2020, 2025 and 2030 (USD Million)
  • Figure 18.1: Survey Insights: Distribution of Respondents by Year of Establishment of the Company
  • Figure 18.2: Survey Insights: Distribution of Respondents by Company Size
  • Figure 18.3: Survey Insights: Distribution of Respondents by Location of Company Headquarters (Region-Wise)
  • Figure 18.4: Survey Insights: Distribution of Respondents by Location of Company Headquarters (Country-Wise)
  • Figure 18.5: Survey Insights: Distribution of Respondents by Designation and Seniority Level
  • Figure 18.6: Survey Insights: Distribution by Focus Area
  • Figure 18.7: Survey Insights: Distribution by Type of 3D Cell Culture Products Offered
  • Figure 18.8: Survey Insights: Distribution by Status of Development of Product(s)
  • Figure 18.9: Survey Insights: Distribution by Method of Fabrication Used
  • Figure 18.10: Survey Insights: Distribution by Source of Cultured Cells
  • Figure 18.11: Survey Insights: Distribution by Key Applications
  • Figure 18.12: Survey Insights: Distribution by 3D Cell Culture Services Offered
  • Figure 18.13: Survey Insights: Distribution by Current and Future Market Opportunity, 2020 and 2030
  • Figure 19.1: 3D Cell Culture Systems Market: Concluding Remarks